JP2013541576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541576A5 JP2013541576A5 JP2013537158A JP2013537158A JP2013541576A5 JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5 JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- present
- age
- treatment
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000030962 Subcutaneous tissue disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190303 | 2010-11-08 | ||
| EP10190303.7 | 2010-11-08 | ||
| EP11151059.0 | 2011-01-17 | ||
| EP11151059 | 2011-01-17 | ||
| PCT/EP2011/069532 WO2012062698A1 (en) | 2010-11-08 | 2011-11-07 | Pharmaceutical composition, methods for treating and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Division JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013541576A JP2013541576A (ja) | 2013-11-14 |
| JP2013541576A5 true JP2013541576A5 (https=) | 2014-10-23 |
Family
ID=44906182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537158A Pending JP2013541576A (ja) | 2010-11-08 | 2011-11-07 | 医薬組成物、治療方法及びその使用 |
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US20120283169A1 (https=) |
| EP (2) | EP3539540B1 (https=) |
| JP (3) | JP2013541576A (https=) |
| KR (3) | KR102051285B1 (https=) |
| CN (2) | CN103282030A (https=) |
| AP (1) | AP2013006813A0 (https=) |
| AR (1) | AR083787A1 (https=) |
| AU (1) | AU2011328231B2 (https=) |
| BR (1) | BR112013011968A2 (https=) |
| CA (1) | CA2813661C (https=) |
| CL (1) | CL2013001104A1 (https=) |
| CO (1) | CO6781465A2 (https=) |
| DK (1) | DK3539540T3 (https=) |
| EA (1) | EA026712B1 (https=) |
| EC (1) | ECSP13012661A (https=) |
| ES (1) | ES3012504T3 (https=) |
| FI (1) | FI3539540T3 (https=) |
| HR (1) | HRP20250096T1 (https=) |
| HU (1) | HUE070541T2 (https=) |
| IL (1) | IL225597A0 (https=) |
| LT (1) | LT3539540T (https=) |
| MA (1) | MA34640B1 (https=) |
| MX (2) | MX356491B (https=) |
| NZ (1) | NZ608829A (https=) |
| PE (1) | PE20140244A1 (https=) |
| PH (2) | PH12013500809A1 (https=) |
| PL (1) | PL3539540T3 (https=) |
| RS (1) | RS66479B1 (https=) |
| SG (1) | SG189249A1 (https=) |
| SI (1) | SI3539540T1 (https=) |
| WO (1) | WO2012062698A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| DK2396005T3 (da) | 2009-02-13 | 2026-02-09 | Boehringer Ingelheim Int | Sglt2 hæmmer til at forbedre glykæmisk kontrol |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| EA020798B1 (ru) | 2009-09-30 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА |
| PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| ES2969764T3 (es) | 2013-12-17 | 2024-05-22 | Boehringer Ingelheim Vetmedica Gmbh | Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos |
| CN115671290A (zh) | 2014-01-23 | 2023-02-03 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| WO2015150299A2 (en) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| WO2016046150A1 (en) | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| CN104473920A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种用于治疗2型糖尿病的复方制剂及其制备方法 |
| KR102659761B1 (ko) | 2015-08-27 | 2024-04-24 | 베링거잉겔하임베트메디카게엠베하 | Sglt-2 억제제를 포함하는 액상 약제학적 조성물 |
| KR20190084096A (ko) | 2016-11-10 | 2019-07-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CN110092768A (zh) * | 2018-04-23 | 2019-08-06 | 中国科学院成都生物研究所 | 包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法 |
| KR20220038339A (ko) * | 2019-07-23 | 2022-03-28 | 노파르티스 아게 | Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료 |
| CN110327355B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和sglt-2抑制剂的组合产品 |
| AU2020341562B2 (en) * | 2019-09-04 | 2026-03-19 | The Regents Of The University Of Michigan | Inhibitors of SGLT and uses thereof |
| US20210093698A1 (en) * | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
| WO2025007870A1 (zh) * | 2023-07-04 | 2025-01-09 | 连云港市瓦尔生物医药科技有限公司 | 一种控制血糖的药物组合试剂盒 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100591585B1 (ko) | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| EP1344780A4 (en) | 2000-11-30 | 2004-01-28 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION |
| ATE431830T1 (de) | 2000-12-28 | 2009-06-15 | Kissei Pharmaceutical | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
| MXPA04009229A (es) | 2002-03-22 | 2004-11-26 | Kissei Pharmaceutical | Cristales derivados de glucopiranosiloxibencil benceno. |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| ES2363941T3 (es) | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| CN103030617A (zh) | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| DE602005009745D1 (de) | 2004-12-16 | 2008-10-23 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| AU2006289093A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7803778B2 (en) | 2006-05-23 | 2010-09-28 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| WO2008020011A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| AU2007316613B2 (en) | 2006-11-09 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| RS56990B1 (sr) | 2007-09-10 | 2018-05-31 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt |
| JP5695909B2 (ja) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
| MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
| CN101503399B (zh) * | 2008-02-04 | 2012-06-27 | 白鹭医药技术（上海）有限公司 | C-芳基葡萄糖苷sglt2抑制剂 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| US20110014284A1 (en) | 2009-02-13 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| DK2396005T3 (da) | 2009-02-13 | 2026-02-09 | Boehringer Ingelheim Int | Sglt2 hæmmer til at forbedre glykæmisk kontrol |
| SG2014012553A (en) * | 2009-04-16 | 2014-05-29 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions |
| JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| EP2552442A1 (en) * | 2010-03-30 | 2013-02-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP5876170B2 (ja) * | 2015-01-13 | 2016-03-02 | 株式会社平和 | 遊技機 |
-
2011
- 2011-11-02 US US13/287,216 patent/US20120283169A1/en not_active Abandoned
- 2011-11-07 HU HUE19163940A patent/HUE070541T2/hu unknown
- 2011-11-07 LT LTEP19163940.0T patent/LT3539540T/lt unknown
- 2011-11-07 EP EP19163940.0A patent/EP3539540B1/en active Active
- 2011-11-07 MX MX2013005095A patent/MX356491B/es active IP Right Grant
- 2011-11-07 SI SI201132125T patent/SI3539540T1/sl unknown
- 2011-11-07 WO PCT/EP2011/069532 patent/WO2012062698A1/en not_active Ceased
- 2011-11-07 PL PL19163940.0T patent/PL3539540T3/pl unknown
- 2011-11-07 CN CN201180064091XA patent/CN103282030A/zh active Pending
- 2011-11-07 RS RS20250115A patent/RS66479B1/sr unknown
- 2011-11-07 MX MX2018006655A patent/MX374694B/es unknown
- 2011-11-07 SG SG2013024849A patent/SG189249A1/en unknown
- 2011-11-07 AP AP2013006813A patent/AP2013006813A0/xx unknown
- 2011-11-07 ES ES19163940T patent/ES3012504T3/es active Active
- 2011-11-07 NZ NZ608829A patent/NZ608829A/en unknown
- 2011-11-07 AR ARP110104151A patent/AR083787A1/es unknown
- 2011-11-07 PE PE2013000955A patent/PE20140244A1/es not_active Application Discontinuation
- 2011-11-07 CA CA2813661A patent/CA2813661C/en active Active
- 2011-11-07 DK DK19163940.0T patent/DK3539540T3/da active
- 2011-11-07 KR KR1020187022985A patent/KR102051285B1/ko active Active
- 2011-11-07 CN CN201610579791.7A patent/CN106177957A/zh active Pending
- 2011-11-07 HR HRP20250096TT patent/HRP20250096T1/hr unknown
- 2011-11-07 KR KR1020137011966A patent/KR20130125365A/ko not_active Ceased
- 2011-11-07 JP JP2013537158A patent/JP2013541576A/ja active Pending
- 2011-11-07 BR BR112013011968A patent/BR112013011968A2/pt not_active IP Right Cessation
- 2011-11-07 KR KR1020197034873A patent/KR102232451B1/ko active Active
- 2011-11-07 AU AU2011328231A patent/AU2011328231B2/en active Active
- 2011-11-07 FI FIEP19163940.0T patent/FI3539540T3/fi active
- 2011-11-07 EP EP11778916.4A patent/EP2637648A1/en not_active Withdrawn
- 2011-11-07 EA EA201300550A patent/EA026712B1/ru not_active IP Right Cessation
- 2011-11-07 PH PH1/2013/500809A patent/PH12013500809A1/en unknown
-
2013
- 2013-04-07 IL IL225597A patent/IL225597A0/en unknown
- 2013-04-22 CL CL2013001104A patent/CL2013001104A1/es unknown
- 2013-05-02 MA MA35865A patent/MA34640B1/fr unknown
- 2013-05-08 CO CO13115446A patent/CO6781465A2/es not_active Application Discontinuation
- 2013-06-04 EC ECSP13012661 patent/ECSP13012661A/es unknown
-
2014
- 2014-01-17 US US14/157,678 patent/US20140256624A1/en not_active Abandoned
-
2015
- 2015-05-15 JP JP2015100121A patent/JP6141907B2/ja active Active
-
2017
- 2017-02-06 JP JP2017019822A patent/JP6515121B2/ja active Active
-
2018
- 2018-03-08 US US15/915,396 patent/US20180193427A1/en not_active Abandoned
- 2018-04-06 PH PH12018500767A patent/PH12018500767A1/en unknown
-
2020
- 2020-03-18 US US16/822,360 patent/US20200397867A1/en not_active Abandoned
-
2021
- 2021-08-12 US US17/400,221 patent/US20220152159A1/en not_active Abandoned
-
2024
- 2024-06-18 US US18/746,567 patent/US20240335514A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541576A5 (https=) | ||
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
| Mokta et al. | Insulin lipodystrophy and lipohypertrophy | |
| Enginyurt et al. | The role of pure honey in the treatment of diabetes mellitus | |
| Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter indian study | |
| Chakraborty et al. | Distant site lipoatrophy: a rare complication of subcutaneous insulin therapy | |
| Ghosal et al. | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India | |
| Heinemann et al. | Integrated personalized diabetes management (iPDM) in patients with insulin-treated T2DM: Results of the PDM-ProValue study program | |
| Kara et al. | Efficacy and safety of sirolimus (mTOR inhibitor) in two patients with diazoxide-unresponsive hyperinsulinemic hypoglycemia | |
| WANG et al. | Investigation and nursing strategy of the current status of insulin therapy in 450 children with type 1 diabetes mellitus | |
| WO2012141764A3 (en) | Pre-operative use of metabolic activation therapy | |
| Triplitt | Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? | |
| Vinik | Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus | |
| Annabestani et al. | Insulin buccal spray (Oral-Lyn) efficacy in type 1 diabetes | |
| Hompesch et al. | Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes | |
| Tarigan et al. | Strategy of insulin intensification after basal failure for type 2 diabetes in the outpatient setting | |
| Striano et al. | Hemidystonia in uncontrolled type 2 diabetes mellitus | |
| Cao | Diabetic ketoacidosis: case report | |
| Ridderstråle et al. | Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 2 years in patients with type 2 diabetes (T2DM) | |
| KK et al. | Prevalence of Diabetic Retinopathy and Associated Factors in Type 2 Diabetes in a Tertiary Care Centre in Kannur District of Kerala | |
| Lehman et al. | No to QOF target of less than 7%, again | |
| M Junaid et al. | Comorbidities in patients requiring dental extraction | |
| Chang | Diabetic muscle infarction: case report | |
| de Bie | 30 An latrogenic Catatonia |